Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and ...

Researchers conducted a target trial emulation to compare the effects of SGLT-2 inhibitor and DPP-4 inhibitor use on epilepsy among patients with type 2 diabetes.

GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors. The study utilized health ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

"DPP-4 inhibitor medications were more widely available despite their lack of similar benefits [to GLP-1 receptor agonists]," they said. Out of 273 non-elderly adult MCO plans in 39 states ...

In contrast, 42 states had a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is considered a second-line agent, available. Of the 273 Medicaid managed care organizations, 66.7% had an SGLT2 inhibitor ...

Compared with DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

The GLMs assessed in the study include GLP-1 receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, insulin, thiazolidinediones, sulfonylureas and dipeptidyl peptidase-4 ...